-
Therapeutic Drug Monitoring and Selective Use of Glucarpidase in High-Dose Methotrexate Therapy: A Cost Analysis From the Algerian Payer Perspective
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective
Sep 9, 2025, 16:22 PM -
Development of an AI-Powered Command-Line Agent to Support Methodological Guidance Selection in Health Economics Analysis
Sep 9, 2025, 16:22 PM -
Lipid-Lowering Prescription Patterns After a Nonfatal Acute Coronary Syndrome: The Impact of Real-World Evidence on Clinical Practice With LATINO-ACS 2.0
Sep 9, 2025, 16:22 PM -
Evaluating Bayesian Borrowing Methods for Treatment Effect Extrapolation: A Simulation-Based Study
Sep 9, 2025, 16:22 PM -
Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data
Sep 9, 2025, 16:22 PM -
Ukraine’s First Horizon Scanning Pilot: Lessons for HTA Implementation
Sep 9, 2025, 16:22 PM -
Health Technology Assessment Landscape for Medical Devices in Europe
Sep 9, 2025, 16:22 PM -
The Hidden Clinical and Economic Costs of PPI Treatment Failures in Severe Erosive Esophagitis
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study
Sep 9, 2025, 16:22 PM -
Leveraging Real-World Data to Conduct Noninterventional Studies in Rare Disease Populations: Lessons in Scalability and Data Access From Three Observational Studies
Sep 9, 2025, 16:22 PM -
Approaches Used in Assessing the Environmental Sustainability of Digital Health Technologies: A Systematic Review
Sep 9, 2025, 16:22 PM -
Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Ukraine and in Kiev City, Lviv, and Cherkasy Regions
Sep 9, 2025, 16:22 PM -
Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing Source Exploration...
Sep 9, 2025, 16:22 PM -
Have Delays in Vaccine Market Access Improved in Europe and the US Over the Last Decade?
Sep 9, 2025, 16:22 PM -
Cardiovascular Event Rate and Mortality Among Primary-Prevention Hypercholesterolemia Patients in Japan
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness as Part of the German AMNOG Process Analyzing the 2025 SVR Proposal and Its Implementation Challenges
Sep 9, 2025, 16:22 PM -
Estimating the Broader Societal Impact of Ocrelizumab for Multiple Sclerosis (MS) in Latin America (LATAM) Using a Social Impact Approach
Sep 9, 2025, 16:22 PM -
Balancing Innovation and Propriety: The Question of Copyright Holder’s Opinions on GenAI Usage While Localizing Their Intellectual Property
Sep 9, 2025, 16:22 PM -
Quality of Life of Patients Living With Epilepsy in Hungary
Sep 9, 2025, 16:22 PM
